Peter B. Berger

Q: What Schools Are Affiliated With Peter B. Berger

Peter B. Berger is affiliated with the following schools: Vanderbilt University, Stanford University, Baylor College of Medicine, University of Iowa, Johns Hopkins University, Columbia University, Duke University, University of Florida College of Medicine, Harvard University, University of Cincinnati, University of Kentucky, Stony Brook University

Peter B. Berger's AcademicInfluence.com Rankings

Peter B. Berger

Philosophy

#6410

World Rank

#9444

Historical Rank

Logic

#3632

World Rank

#4823

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Peter B. Berger's Degrees

Doctorate Medicine Harvard University
PhD Cardiology Johns Hopkins University

Why Is Peter B. Berger Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Peter B. Berger is the Senior Vice President of Clinical Research throughout the North Shore Long Island Jewish Health Care System, the nation's 14th largest health care system, and the one of the largest non-profit systems. He is also a Professor of Cardiology and of Medicine in the Hofstra North Shore - LIJ School of Medicine. Berger practices interventional cardiology at North Shore Hospital.

(See a Problem?)

Peter B. Berger's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. (2002) (3094)
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. (2006) (2183)
Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention (2002) (1653)
ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery---executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluat (2002) (1523)
Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden: Results From the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy (2008) (1505)
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. (2011) (1036)
Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta‐analysis (2010) (923)
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (842)
Variability in platelet responsiveness to clopidogrel among 544 individuals. (2005) (806)
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. (2006) (779)
The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. (2002) (720)
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. (2005) (698)
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. (2007) (625)
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. (2004) (582)
Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. (1999) (574)
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study (2013) (532)
Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. (2003) (498)
Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. (2008) (481)
ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluati (2002) (479)
Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative (2004) (427)
Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial (2011) (400)
Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. (2002) (383)
Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1995) (376)
Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. (2007) (361)
Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study (2001) (360)
American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on cardiac catheterization laboratory standards. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. (2001) (353)
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. (2008) (344)
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. (2005) (332)
Inferior myocardial infarction. High-risk subgroups. (1990) (315)
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. (2002) (294)
Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial (2003) (286)
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. (2011) (285)
Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. (2005) (282)
Immediate and long-term outcome of intracoronary stent implantation for true bifurcation lesions. (2000) (274)
Independent Association Between Plasma Leptin and C-Reactive Protein in Healthy Humans (2004) (264)
Plasma leptin and prognosis in patients with established coronary atherosclerosis. (2004) (251)
Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events Published, JLR Papers in Press, November 8, 2006. (2007) (248)
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. (2005) (240)
Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. (2005) (232)
Outcomes of Patients With Chronic Renal Insufficiency in the Bypass Angioplasty Revascularization Investigation (2002) (227)
The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (224)
Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. (1999) (224)
Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting (2011) (222)
Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. (1997) (220)
Initial and Long‐term Outcome of 354 Patients After Coronary Balloon Angioplasty of Total Coronary Artery Occlusions (1992) (212)
A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. (2009) (211)
ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery--Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluat (2002) (204)
Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (201)
Perioperative management of patients with coronary stents. (2007) (201)
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. (2004) (199)
Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease: Results From the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial (2010) (197)
Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. (2006) (196)
Coronary artery stents. (1996) (194)
Body Mass Index: A Risk Factor for Unstable Angina and Myocardial Infarction in Patients With Angiographically Confirmed Coronary Artery Disease (2003) (193)
Long-Term Clinical Outcome in the Bypass Angioplasty Revascularization Investigation Registry Comparison With the Randomized Trial (2000) (189)
Incidence, correlates, management, and clinical outcome of coronary perforation: analysis of 16,298 procedures. (2004) (184)
Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding (2009) (183)
Hyperhomocysteinemia accelerates atherosclerosis in cystathionine beta-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. (2003) (183)
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. (2008) (182)
A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators. (1995) (172)
Cardiogenic shock complicating acute coronary syndromes (2000) (171)
Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. (2002) (166)
Clopidogrel versus ticlopidine after intracoronary stent placement. (1999) (163)
Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. (2004) (163)
Adverse Prognosis of Patients With Hypertrophic Cardiomyopathy Who Have Epicardial Coronary Artery Disease (2003) (152)
ACC/AHA Guideline Update on Perioperative Cardiovascular Evaluation for Noncardiac Surgery (2002) (152)
Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. (2010) (151)
The changing in-hospital mortality of women undergoing percutaneous transluminal coronary angioplasty. (1993) (146)
Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. (2009) (145)
Abstract 3999: Baseline Proton Pump Inhibitor Use is Associated with Increased Cardiovascular Events With and Without the Use of Clopidogrel in the CREDO Trial (2008) (143)
The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. (2009) (137)
Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. (2006) (136)
Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease (2009) (131)
Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. (2000) (127)
Systems of Care for ST-Segment–Elevation Myocardial Infarction: A Report From the American Heart Association’s Mission: Lifeline (2012) (124)
Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. (2004) (122)
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. (2007) (120)
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting: A North American Perspective: Executive Summary (2011) (119)
Estimates of myocardium at risk and collateral flow in acute myocardial infarction using electrocardiographic indexes with comparison to radionuclide and angiographic measures. (1995) (119)
Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). (2009) (119)
Validity of International Classification of Disease Codes to Identify Ischemic Stroke and Intracranial Hemorrhage Among Individuals With Associated Diagnosis of Atrial Fibrillation (2015) (118)
Frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the Thrombolysis in Myocardial Infarction [TIMI] II trial) (1993) (117)
Immediate and late outcomes after direct stent implantation without balloon predilation. (2000) (115)
Optimal Timing of Intervention in Non–ST-Segment Elevation Acute Coronary Syndromes: Insights From the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry (2005) (115)
Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II. (1992) (113)
Association between plasma adiponectin levels and unstable coronary syndromes. (2007) (113)
Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. (2007) (112)
Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). (2014) (112)
Influence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current era (the Mayo Clinic experience). (2001) (110)
Troponin criteria for myocardial infarction after percutaneous coronary intervention. (2012) (109)
Antithrombotic therapy in patients undergoing percutaneous coronary intervention. (2001) (107)
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. (2012) (107)
Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival (2003) (106)
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial (1997) (106)
Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. (1999) (106)
Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. (2003) (103)
One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial. (1999) (103)
Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. (2011) (102)
Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel: Results From the Interaction Study (2004) (102)
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. (2008) (98)
Association of body mass index with outcome after percutaneous coronary intervention. (2003) (97)
Referral for coronary artery revascularization procedures after diagnostic coronary angiography: evidence for gender bias? (1995) (94)
Plasma Ceramides: A Novel Predictor of Major Adverse Cardiovascular Events After Coronary Angiography (2018) (94)
Outcome of patients undergoing balloon angioplasty in the two months prior to noncardiac surgery. (2005) (94)
Long-term outcome of women compared with men after successful coronary angioplasty. (1995) (93)
Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Results from the Bypass Angioplasty Revascularization Investigation (BARI). (2001) (93)
Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting. (2011) (93)
Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study). (2004) (90)
Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. (1999) (88)
Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. (1996) (88)
Management of Patients Undergoing Percutaneous Coronary Revascularization (2003) (88)
Clinical safety of magnetic resonance imaging early after coronary artery stent placement. (2003) (87)
Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease. (2003) (87)
Impact of Regionalization of ST-Segment–Elevation Myocardial Infarction Care on Treatment Times and Outcomes for Emergency Medical Services–Transported Patients Presenting to Hospitals With Percutaneous Coronary Intervention: Mission Lifeline Accelerator-2 (2017) (86)
Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATO (1996) (84)
Predictors of improvement in left ventricular function after percutaneous revascularization of occluded coronary arteries: a report from the Total Occlusion Study of Canada (TOSCA). (2001) (84)
Frequency of early occlusion and stenosis in a left internal mammary artery to left anterior descending artery bypass graft after surgery through a median sternotomy on conventional bypass: benchmark for minimally invasive direct coronary artery bypass. (1999) (83)
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. (2009) (83)
Early and 1-year clinical outcome of patients' evolving non-Q-wave versus Q-wave myocardial infarction after thrombolysis. Results from The TIMI II Study. (1995) (80)
American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on Cardiac Catheterization Laboratory Standards (2001) (79)
Effect of age on the outcome of angioplasty for acute myocardial infarction among patients treated at the Mayo Clinic. (2000) (79)
Balloon angioplasty of chronic total coronary artery occlusions: what does it cost in radiation exposure, time, and materials? (1992) (76)
Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial. (2004) (76)
Renal function, concomitant medication use and outcomes following acute coronary syndromes. (2005) (75)
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase Results from GUSTO-III (1999) (75)
Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. (2004) (73)
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). (2003) (72)
Cardiovascular disease and chronic kidney disease: insights and an update. (2004) (72)
Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): study design. (2006) (70)
Antithrombotic therapy during percutaneous coronary intervention: The seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy (2005) (70)
Regional Systems of Care Demonstration Project: American Heart Association Mission: Lifeline STEMI Systems Accelerator. (2016) (68)
Increase in total plasma homocysteine concentration after cardiac transplantation. (1995) (68)
Society of cardiac angiography and interventions: Suggested management of the no‐reflow phenomenon in the cardiac catheterization laboratory (2003) (67)
Prevalence and Prognostic Significance of Preprocedural Cardiac Troponin Elevation Among Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results From the Evaluation of Drug Eluting Stents and Ischemic Events Registry (2008) (66)
Application of the New York State PTCA mortality model in patients undergoing stent implantation. (2000) (65)
Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: Results from the thrombolysis in myocardial infarction (TIMI) phaes II trial (1993) (64)
Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. (2010) (63)
Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending disease. (2014) (60)
Outcome > or = 10 years after successful percutaneous transluminal coronary angioplasty. (1997) (59)
Methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms: association with serum homocysteine and angiographic coronary artery disease in the era of flour products fortified with folic acid. (2003) (59)
The Primary and Secondary Prevention of Coronary Artery Disease (2008) (59)
Acute myocardial infarction complicated by heart block in the elderly: prevalence and outcomes. (2001) (58)
Prognostic Value of Access and Non–Access Sites Bleeding After Percutaneous Coronary Intervention (2013) (57)
Primary percutaneous coronary interventions in patients with acute myocardial infarction and prior coronary artery bypass grafting. (2001) (57)
One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. (2008) (56)
An immediate invasive strategy for the treatment of acute myocardial infarction early after noncardiac surgery. (2001) (55)
First experience with direct, selective factor Xa inhibition in patients with non‐ST‐elevation acute coronary syndromes: results of the XaNADU‐ACS Trial (2005) (55)
In-hospital and long-term outcomes of multivessel percutaneous coronary revascularization after acute myocardial infarction. (2005) (54)
Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). (2006) (52)
Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent? (2016) (51)
Impact of Proton Pump Inhibitor Therapy on the Efficacy of Clopidogrel in the CAPRIE and CREDO Trials (2013) (51)
The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. (2005) (51)
Patients With Chronic Total Occlusions Undergoing Percutaneous Coronary Interventions: Characteristics, Success, and Outcomes (2016) (51)
Time to reperfusion with direct coronary angioplasty and thrombolytic therapy in acute myocardial infarction. (1994) (50)
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. (2011) (49)
Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization. (2004) (49)
Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI Investigators. (2000) (49)
Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. (2008) (48)
One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. (2005) (48)
Clinical Implications of Percutaneous Coronary Intervention-Clopidogrel in Unstable angina to prevent Recurrent Events (PCI-CURE) Study: A US Perspective (2002) (48)
Predictors of reperfusion delay in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention from the HORIZONS-AMI trial. (2010) (48)
Treatment of Saphenous Vein Bypass Grafts With Ultrasound Thrombolysis: A Randomized Study (ATLAS) (2003) (47)
Readmission in the 30 days after percutaneous coronary intervention. (2013) (47)
Quantitative Results of Baseline Angiography and Percutaneous Coronary Intervention in the COURAGE Trial (2009) (47)
Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. (2003) (47)
Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. (2015) (46)
Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial. (2009) (46)
Association of Rapid Care Process Implementation on Reperfusion Times Across Multiple ST-Segment–Elevation Myocardial Infarction Networks (2017) (45)
Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction. (2001) (44)
Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. (2009) (44)
Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. (2002) (44)
Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. (2004) (43)
Red cell distribution width is a predictor of mortality in patients undergoing percutaneous coronary intervention (2012) (43)
Frequency and time course of reocclusion and restenosis in coronary artery occlusions after balloon angioplasty versus Wiktor stent implantation: results from the Mayo-Japan Investigation for Chronic Total Occlusion (MAJIC) trial. (2004) (41)
Rationale for on-site cardiac surgery for primary angioplasty: a time for reappraisal. (2002) (41)
Paramedic transtelephonic communication to cardiologist of clinical and electrocardiographic assessment for rapid reperfusion of ST-elevation myocardial infarction. (2007) (41)
Assessing the Current Role of Platelet Function Testing (2008) (40)
The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention (2008) (40)
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. (2005) (40)
Age dependence of the influence of methylenetetrahydrofolate reductase genotype on plasma homocysteine level. (2003) (40)
The effect of estrogen replacement therapy on total plasma homocysteine in healthy postmenopausal women. (2000) (40)
Comparison of immediate and long-term outcome of coronary angioplasty performed for unstable angina and rest pain in men and women. (1997) (40)
Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?: Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial (2012) (39)
Temporal Trends in the Incidence, Prevalence, and Survival of Patients With Atrial Fibrillation From 2004 to 2016. (2017) (38)
A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. (2001) (38)
Troponisms, necrosettes, enzyme leaks, creatinine phosphokinase bumps, and infarctlets: what's behind this new lexicon and what does it add? (2001) (38)
Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure. (2001) (38)
Allergic Reactions to Clopidogrel and Cross-Reactivity to Other Agents (2011) (37)
Age-Dependent Effect of Abciximab in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions (2006) (36)
Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel. (2009) (36)
Results of directional atherectomy of primary atheromatous and restenosis lesions in coronary arteries and saphenous vein grafts. (1992) (36)
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). (2003) (36)
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Stroke in Patients with a History of Atrial Fibrillation: Subgroup Analysis of the CHARISMA Randomized Trial (2008) (35)
Changes in Percutaneous Coronary Interventions Deemed "Inappropriate" by Appropriate Use Criteria. (2017) (35)
Identification, Diagnosis and Treatment of Heparin-induced Thrombocytopenia and Thrombosis: A Registry of Prolonged Heparin Use and Thrombocytopenia among Hospitalized Patients with and without Cardiovascular Disease (2005) (35)
The changing face of coronary interventional practice. The Mayo Clinic experience. (1997) (34)
Prediction of death after percutaneous coronary interventional procedures. (2000) (34)
Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] trial). (2007) (33)
Utility of bilateral coronary injections during complex coronary angioplasty. (1999) (33)
Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. (1993) (33)
Intercenter variability in outcome for patients treated with direct coronary angioplasty during acute myocardial infarction. (1998) (33)
Delays in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients Presenting With Cardiogenic Shock. (2018) (33)
Clinical outcome of patients undergoing endoluminal coronary artery reconstruction with three or more stents. (1997) (32)
Risk Stratification for Long-Term Mortality After Percutaneous Coronary Intervention (2014) (32)
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. (1999) (32)
Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin). (1998) (32)
Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial. (2011) (31)
Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. (2016) (31)
Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials (2008) (30)
The New York State risk score for predicting in-hospital/30-day mortality following percutaneous coronary intervention. (2013) (30)
Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality. (2010) (30)
Distal protection devices during percutaneous coronary and carotid interventions (2001) (30)
Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial (2010) (29)
Safety of coronary angiography and percutaneous coronary intervention via the radial versus femoral route in patients on uninterrupted oral anticoagulation with warfarin. (2014) (29)
Comparison of intermediate-term outcomes of coronary artery bypass grafting versus drug-eluting stents for patients ≥75 years of age. (2014) (29)
Clopidogrel instead of ticlopidine after coronary stent placement: is the switch justified? (2000) (28)
Relationship Between Baseline Inflammatory Markers, Antiplatelet Therapy, and Adverse Cardiac Events After Percutaneous Coronary Intervention: An Analysis From the Clopidogrel for the Reduction of Events During Observation Trial (2009) (28)
Comparison of percutaneous interventions for unstable angina pectoris in patients with and without previous coronary artery bypass grafting. (2000) (28)
Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. (2007) (27)
Time to reperfusion and other procedural characteristics of emergency coronary artery bypass surgery after unsuccessful coronary angioplasty. (1995) (27)
Improving outcome over time of percutaneous coronary interventions in unstable angina. (2000) (26)
Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry. (2011) (26)
Usefulness of abciximab for treatment of early coronary artery stent thrombosis. (1998) (26)
Interventional cardiology and intracoronary stents--a changing practice: approved vs. nonapproved indications. (1997) (25)
Regional Systems of Care Demonstration ProjectClinical Perspective (2016) (24)
Frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the thrombolysis in myocardial infarction [TIMI] II trial). The TIMI Research Group. (1993) (24)
Predictors of major ischemic complications after coronary dissection following angioplasty. (1993) (24)
Association of Coronary Vessel Characteristics With Outcome in Patients With Percutaneous Coronary Interventions With Incomplete Revascularization (2017) (24)
Restrictive cardiomyopathy associated with the eosinophilia-myalgia syndrome. (1994) (24)
Neointimal response following rotational atherectomy compared to balloon angioplasty in a porcine model of coronary in-stent restenosis. (1998) (24)
Preoperative aspirin is safe in patients undergoing urologic robot-assisted surgery. (2012) (23)
Influence of procedural success on immediate and long-term clinical outcome of patients undergoing percutaneous revascularization of occluded coronary artery bypass vein grafts. (1996) (23)
Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. (2001) (22)
Percutaneous coronary intervention for ST-segment and non-ST-segment elevation myocardial infarction at hospitals with and without on-site cardiac surgical capability. (2004) (22)
Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement? (2000) (21)
Impact of pre‐hospital electrocardiograms on time to treatment and one year outcome in a rural regional ST‐segment elevation myocardial infarction network (2017) (21)
The thienopyridines. (2002) (21)
Does Preoperative Platelet Function Predict Bleeding in Patients Undergoing Off Pump Coronary Artery Bypass Surgery? (2015) (21)
Should bare metal or drug‐eluting stents be used during PCI of saphenous vein graft lesions: Waiting for Godot? (2008) (21)
Lack of association between plasma homocysteine and angiographic coronary artery disease in the era of fortification of cereal grain flour with folic acid. (2002) (21)
Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial. (2007) (20)
Effectiveness and safety of abciximab after failed thrombolytic therapy. (2001) (20)
Optimal duration of clopidogrel use after implantation of drug-eluting stents--still in doubt. (2010) (20)
Choosing between percutaneous coronary intervention and coronary artery bypass grafting for patients with multivessel disease: what can we learn from the Arterial Revascularization Therapy Study (ARTS)? (2004) (20)
Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial (2017) (19)
One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial. (2013) (19)
The risk of drug-eluting stent thrombosis with noncardiac surgery (2007) (18)
Threshold values for preserved viability with a noninvasive measurement of collateral blood flow during acute myocardial infarction treated by direct coronary angioplasty. (1999) (18)
Percutaneous revascularization of occluded vein grafts : is it still a temptation to be resisted? (1999) (18)
Safety and efficacy of cutting balloon angioplasty: the Mayo Clinic experience. (2002) (18)
Routine intravascular ultrasound scanning guidance of coronary stenting is not associated with improved clinical outcomes. (2004) (18)
Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program. (2010) (17)
Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation (2017) (17)
Coronary angioplasty in acute myocardial infarction: primary, immediate adjunctive, rescue, or deferred adjunctive approach? (1994) (17)
Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials (2008) (17)
Relationship between age-related macular degeneration-associated variants of complement factor H and LOC387715 with coronary artery disease. (2007) (17)
Prevalence and outcomes of intermediate saphenous vein graft lesions: findings from the stenting of saphenous vein grafts randomized-controlled trial. (2013) (16)
Routine intravascular ultrasound scanning guidance of coronary stenting is not associated with improved clinical outcomes (2004) (16)
Relationship Between Baseline Inflammatory Markers, Antiplate let Therapy, and Adverse Cardiac Events After Percutaneous Coronary Intervention (2009) (16)
Emergency pretreatment for contrast allergy before direct percutaneous coronary intervention for ST-elevation myocardial infarction. (2008) (16)
Feasibility and safety of ad hoc percutaneous coronary intervention in the modern era. (2009) (15)
Effect of abciximab on the outcome of emergency coronary artery bypass grafting after failed percutaneous coronary intervention. (2001) (15)
Practice Guidelines (8th Edition) of Chest Physicians Evidence-Based Clinical Coronary Artery Disease: American College The Primary and Secondary Prevention of (2008) (15)
Ranolazine and other antianginal therapies in the era of the drug-eluting stent. (2004) (15)
Impact of Regional Systems of Care on Disparities in Care Among Female and Black Patients Presenting With ST‐Segment–Elevation Myocardial Infarction (2017) (15)
Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice: The Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome Prospective Open Label Antiplatelet Therapy Study (2015) (15)
Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: Results from TARGET (do tirofiban and reopro give similar efficacy trial?) (2007) (14)
The effect of antiplatelet and anticoagulant therapy on the clinical outcome of patients undergoing ureteroscopy. (2013) (14)
The thienopyridines in coronary artery disease (1999) (14)
Paroxysmal atrial fibrillation and the hazards of under-treatment. (2016) (14)
Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction Before and During COVID in New York (2020) (14)
Utilization of radial artery access for percutaneous coronary intervention for ST-segment elevation myocardial infarction in New York. (2014) (14)
Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation. (2017) (14)
American College of Cardiology/Society for Cardiac Angiography and Interventions clinical expert consensus document on cardiac catheterization laboratory standards: Summary of a report of the American College of Cardiology Task Force on clinical expert consensus documents (2001) (13)
Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment (2008) (13)
In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. (2009) (12)
Disparities in the Use of Drug-Eluting Coronary Stents by Race, Ethnicity, Payer, and Hospital. (2016) (12)
Noninvasive prediction of residual blood flow within the risk area during acute myocardial infarction: a multicenter validation study of patients undergoing direct coronary angioplasty. (1997) (12)
Complications related to access site after percutaneous coronary interventions (2011) (12)
Bleeding is bad.... isn't it? (2007) (12)
Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry). (2009) (12)
Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches (2008) (12)
Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes (2008) (11)
Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women (2005) (11)
Understanding the Adverse Effects of Ticagrelor in Practice. (2016) (11)
The glycoprotein IIb/IIIa inhibitor wars: an update. (2010) (11)
Perioperatives Management der antithrombotischen Therapie: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8. Auflage) (2008) (11)
ST-elevation myocardial infarction patients can be enrolled in randomized trials before emergent coronary intervention without sacrificing door-to-balloon time. (2009) (10)
Is the heat on HEAT-PPCI appropriate? (2014) (10)
Antiplatelet Therapy and Platelet Function Testing (2008) (10)
What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? (2003) (10)
Alveolar hemorrhage associated with periprocedural eptifibatide administration. (2004) (10)
FREQUENCY OF CORONARY ANGIOGRAPHY AND REVASCULARIZATION AMONG MEN AND WOMEN WITH MYOCARDIAL INFARCTION AND THEIR RELATIONSHIP TO MORTALITY AT ONE YEAR: AN ANALYSIS OF THE GEISINGER MYOCARDIAL INFARCTION COHORT (2010) (10)
Frequency of coronary angiography and revascularization among men and women with myocardial infarction and their relationship to mortality at one year: an analysis of the Geisinger myocardial infarction cohort. (2013) (10)
Management of balloon rupture during rigid stent deployment. (1995) (10)
Use of an Electronic Health Record to Optimize Site Performance in Randomized Clinical Trials (2014) (9)
Use of excimer laser in the treatment of chronic total occlusion of a coronary artery that cannot be crossed with a balloon catheter. (1993) (9)
Therapeutic goals for effective platelet inhibition: a consensus document. (2006) (9)
Middle‐of‐the‐night PCI does not affect subsequent day PCI success and complication rates by the same operator (2012) (9)
Incomplete revascularization for percutaneous coronary interventions: Variation among operators, and association with operator and hospital characteristics (2017) (9)
Cardiogenic shock--Beyond the large infarction. (2006) (8)
Aspirin following PCI: too much of a good thing? (2008) (8)
Clinical outcome of patients undergoing multivessel coronary stent implantation. (1998) (8)
Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA). (2001) (8)
Cutting balloon angioplasty vs. conventional balloon angioplasty in patients receiving intracoronary brachytherapy for the treatment of in‐stent restenosis (2004) (7)
Effect of restenosis after an earlier angioplasty at another coronary site on the frequency of restenosis after a subsequent coronary angioplasty. (1992) (7)
IMMEDIATE AND LONG-TERM OUTCOME OF INTRACORONARY STENT IMPLANTATION FOR TRUE BIFURCATION BIFURCATION LESIONS (2000) (7)
In‐Hospital and 1‐year outcomes with drug‐eluting versus bare metal stents in saphenous vein graft intervention: A report from the EVENT registry (2012) (7)
Can euphoria be bad? (2003) (7)
Aspirin, ticlopidine and clopidogrel in and out of the catheterization laboratory. (1999) (7)
Abciximab administration and outcome after intracoronary stent implantation. (1998) (7)
Can ticiopidine be safely discontinued two weeks after coronary stent placement (1998) (6)
Paclitaxel-eluting stents reduce neointimal hyperplasia compared to bare metal stents in saphenous vein grafts: intravascular ultrasonography analysis of the SOS (Stenting of Saphenous Vein Grafts) trial. (2011) (6)
Evaluation for Noncardiac Surgery) (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Cardiology/American Heart Association Task Force on Practice Guidelines Noncardiac Surgery—Executive Summary A Report of the American College of ACC/AHA Guideline Update for Perioperative Card (2008) (6)
Outcomes of unselected recipients of sirolimus-eluting stents: the Cypher stent U.S. post-marketing surveillance registry. (2010) (6)
Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non st-segment elevation myocardial infarction. (2013) (6)
Should proton pump inhibitors be withheld from patients taking clopidogrel? The issue that has been giving me heartburn! (2015) (6)
Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study. (2005) (6)
The Impact of Excluding Shock Patients on Hospital and Physician Risk-Adjusted Mortality Rates for Percutaneous Coronary Interventions: The Implications for Public Reporting. (2017) (6)
Do stents reduce mortality compared with balloon angioplasty? A critical review of all the evidence. (2005) (6)
Effects of tissue plasminogen activator therapy on the frequency of acute right ventricular myocardial infarction associated with acute left ventricular infarction. (1993) (6)
Percutaneous Coronary Intervention With and Without Intravascular Ultrasound for Patients With Complex Lesions: Utilization, Mortality, and Target Vessel Revascularization (2022) (6)
Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial (2011) (6)
Sex differences in the treatment and outcomes of patients hospitalized with ST‐elevation myocardial infarction (2020) (6)
Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). (2011) (6)
Immediate and one-year outcome of intracoronary stent implantation in small coronary arteries with 2.5-mm stents. (2000) (5)
Sunday, 26 August 2012 (2012) (5)
Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. (2015) (5)
Cardiogenic Shock Complicating ST-Segment Elevation Acute Coronary Syndrome (2002) (5)
Timing and correlates of very early major adverse clinical events following percutaneous coronary intervention. (2008) (5)
Ventricular function after primary angioplasty for acute myocardial infarction: correlates and caveats. (2001) (5)
2017 Versus 2012 Appropriate Use Criteria for Percutaneous Coronary Interventions: Impact on Appropriateness Ratings. (2018) (5)
861-1 Direct, selective, factor Xa inhibition in patients with non-ST elevation acute coronary syndromes from the United States, Canada, and Japan: Results of the XaNADU-ACS trial (2004) (5)
Effect of bare metal stenting on angiographic and clinical outcomes in diabetic and nondiabetic patients undergoing percutaneous coronary intervention of nonacute occluded coronary arteries: A report from the total occlusion study of Canada (TOSCA) (2005) (5)
Abstract 8423: Prevalence and Outcomes of Intermediate Saphenous Vein Graft Lesions: Findings from the Stenting of Saphenous Vein Grafts Randomized-Controlled Trial (2011) (4)
Intracoronary glycoprotein IIb/IIIa inhibitors from questioning the logic to weighing the data. (2010) (4)
THE RISK OF THROMBOEMBOLIC COMPLICATIONS WITHOUT ANTICOAGULATION AFTER SURGICAL AORTIC VALVE REPLACEMENT WITH A BIOPROSTHESIS (2015) (4)
A glucose-insulin-potassium infusion did not reduce mortality, cardiac arrest, or cardiogenic shock after acute MI. (2005) (4)
Incidence and significance of mitral regurgitation following first myocardial infarction treated with rt-PA: Results fron TIMI II (1991) (4)
Abstract 4505: Presentation To Non-PCI Center Is Major Modifiable Factor Associated With Delayed Door-to-balloon Time In HORIZONS-AMI (2008) (4)
The Association of Socio-Economic Factors with Percutaneous Coronary Intervention Outcomes. (2021) (4)
Monday, 27 August 2012 (2012) (3)
Reviparin reduced a composite endpoint of death, reinfarction, stroke, and ischemia at 7 and 30 days after acute MI. (2005) (3)
Response to a Differing Perspective: The Real Issues Related to Public Reporting Around Percutaneous Coronary Intervention. (2016) (3)
ORAL ANTICOAGULATION UNDERUSED AND ASPIRIN OVERUSED FOR ATRIAL FIBRILLATION WITH ADVANCED CHRONIC KIDNEY DISEASE STATUS (2019) (3)
Does kidney function alter the benefit of reperfusion therapy for ST-segment elevation myocardial infarction? (2009) (3)
Practice Guidelines (8th Edition) of Chest Physicians Evidence-Based Clinical Antithrombotic Therapy: American College The Perioperative Management of (2008) (3)
Immediate and long-term clinical outcome in patients undergoing angioplasty of occluded vein grafts (1996) (3)
Initial experience with a novel direct factor Xa inhibitor in percutaneous coronary intervention (2002) (3)
One year survival among patients with myocardial infarction complicated by cardiogenic shock alive at 30 days, and the impact of early revascularization: results from GUSTO-1 (1998) (3)
Can percutaneous coronary interventions reduce death and myocardial infarction in stable and unstable coronary disease? (2004) (3)
Cardiovascular surgery abstractSurvival following coronary angioplasty vs. coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Results from the bypass angioplasty revascularization investigation (BARI) (2002) (3)
Routine platelet testing should not be performed on all patients undergoing percutaneous coronary intervention. (2010) (3)
Antiplatelet Therapy and Platelet Function Testing (2008) (3)
Appending Limited Clinical Data to an Administrative Database for Acute Myocardial Infarction Patients: The Impact on the Assessment of Hospital Quality (2016) (3)
Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention (2008) (3)
Initial results and long-term outcome of coronary angioplasty in chronic mild angina pectoris. (1993) (3)
Does Clopidogrel Increase the Degree of Platelet Inhibition When a Platelet Glycoprotein IIb/IIIa Inhibitor Has Been Given? Insights From an Optical Platelet Aggregometry Study (2004) (3)
CRT-33 Peri-procedural CK-MB Levels In Percutaneous Coronary Intervention With High-dose Bolus Tirofiban Vs. Abciximab Plus Either Unfractionated Heparin Or Bivalirudin: An Analysis From TENACITY (2013) (2)
USING INTERNATIONAL CLASSIFICATION OF DISEASES NINTH REVISION CODES OVERESTIMATES THE FREQUENCY OF TRUE STROKE (2013) (2)
Plasma Ceramides Independently Predict Coronary Artery Disease and Major Adverse Cardiovascular Events (2016) (2)
Hybrid coronary revascularization vs. percutaneous coronary interventions for multivessel coronary artery disease (2021) (2)
Modulating Thrombotic Potential in Catheter-Based Percutaneous Coronary and Peripheral Vascular Interventions (2004) (2)
Stents with high-pressure balloon inflations and intravascular ultrasonography--applicable in all patients? (1997) (2)
Outcome of PTCA and stenting in diabetic and nondiabetic patients: a report from the total occlusion study of Canada (TOSCA) investigators (2002) (2)
Abstract 3608: Lipoprotein (a) Cholesterol, But Not Lp(a) Mass, Is An Independent Predictor Of Angiographic Coronary Artery Disease And Subsequent Cardiovascular Events In Patients Referred For Coronary Angiography. (2007) (2)
Pro: standard percutaneous coronary intervention is the procedure of choice for myocardial revascularization. (2003) (2)
1001-8 Long-term results of ISAR-REACT: A randomized trial evaluating Abciximab in patients with elective percutaneous coronary intervention after pretreatment with a high loading dose of clopidogrel (2004) (2)
Does clopidogrel pretreatment counteract the benefits of off-pump CABG surgery? (2006) (2)
Resistance to antiplatelet drugs: Is it real or relevant? (2004) (2)
Impact of stent size and indication for stent placement on immediate outcome. (1996) (2)
Baseline clinical and angiographic variables and long-term outcome after stent implantation (1998) (2)
815-2 Long-term outcome of patients with cardiogenic shock complicating acute myocardial infarction (2004) (2)
"Rescue" directional coronary atherectomy after unsuccessful percutaneous transluminal coronary angioplasty. (1994) (2)
Assessment of repeat target lesion percutaneous coronary intervention as a quality measure for public reporting and general quality assessment for PCIs (2020) (2)
Optimal dosing of a glycoprotein IIb/IIIa antagonist with simplified renal-based algorithm: pharmacodynamic and clinical findings from PARAGON B (2001) (2)
C-B4-02: Enhancing the Quality and Efficiency of Obstructive Sleep Apnea Screening Using Health Information Technology: Results of a Geisinger Clinic Pilot Study (2011) (2)
Clinical experience with percutaneous brachial coronary angiography in a "Judkins" laboratory. (1990) (2)
Treatment of coronary bifurcations: might less be more? (2008) (2)
Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons? (2013) (2)
Lipoprotein(a) Cholesterol But Not Lipoprotein(a) Mass is Significantly Correlated with Angiographic Coronary Artery Disease and Major Adverse Events (2018) (2)
Incidence, management, and outcomes of coronary perforation: An analysis of 16,298 patients (2003) (1)
New developments in the management of ischemic heart disease Commentary (1995) (1)
A CLINICAL PREDICTION MODEL FOR TIME IN THERAPEUTIC RANGE WHILE ON WARFARIN IN NEWLY DIAGNOSED ATRIAL FIBRILLATION (2017) (1)
READMISSIONS FOR MAJOR BLEEDING OR FALLS ARE UNCOMMON IN AN UNSELECTED POPULATION OF PATIENTS HOSPITALIZED WITH ATRIAL FIBRILLATION (2018) (1)
Point-of-care measurement of platelet function before angioplasty strongly predicts future target vessel revascularization (2002) (1)
Abstract 3799: Age-Dependent Effect of Abciximab in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions (2006) (1)
Impact of Switching From Prasugrel to Clopidogrel Shortly After a Percutaneous Coronary Intervention Without a Loading Dose of Clopidogrel. (2015) (1)
INFLUENCE OF SMOKING ON THE ANTIPLATELET EFFECT OF CLOPIDOGREL DIFFERS ACCORDING TO DOSING STRATEGY: INSIGHTS FROM THE GRAVITAS TRIAL (2013) (1)
Assessing Hospital Performance for Acute Myocardial Infarction: How Should Emergency Department Transfers Be Attributed (2015) (1)
PERSISTENT BENEFIT FROM PACLITAXEL-ELUTING STENT IMPLANTATION IN SAPHENOUS VEIN GRAFTS: LONG-TERM RESULTS OF THE STENTING OF SAPHENOUS VEIN GRAFTS (SOS) TRIAL (2010) (1)
P2Y12 Antagonists in Acute Coronary Syndrome: In Whom Should They Be Started, and When? (2011) (1)
1123-180 Incidence and evaluation of heparin-induced thrombocytopenia (HIT) among patients treated with prolonged heparin and among thrombocytopenic patients in the cardiac care unit: Preliminary results of the CATCH registry (2004) (1)
The inter-relationship between creatinine clearance, cardiac troponin T and outcomes in patients with acute coronary syndromes (2002) (1)
PROVIDER- AND HOSPITAL-LEVEL VARIATION IN ORAL ANTICOAGULANT USE FOR STROKE PREVENTION IN ATRIAL FIBRILLATION (2018) (1)
Diabetes mellitus and preferred method of coronary revascularization--the debate continues. (2003) (1)
The Changing Face of Coronary Interventional Practice (2017) (1)
TCT-460 Bivalirudin versus heparin during percutaneous coronary intervention: a meta-analysis of randomized trials (2014) (1)
RATES OF ORAL ANTICOAGULANT USE, WHILE IMPROVING OVER TIME, REMAIN LOW AMONG HOSPITALIZED PATIENTS WITH ATRIAL FIBRILLATION (2017) (1)
715-1 Predictors of Mortality in Cardiogenic Shock: The GUSTO Experience (1995) (1)
TCT-88 Three-year Clinical Outcomes of the First-In-Human Experience with Percutaneous Ventricular Restoration Using the Parachute Device in Patients with Ischemic Heart Failure and Dilated Left Ventricle (2012) (1)
Abstract 1933: Correlates of Bleeding After a 600 mg Loading Dose of Clopidogrel, With and Without Abciximab: A Pooled Analysis of 4 ISAR Randomized Trials. (2007) (1)
Finding the Proper Context for the MATRIX Trial. (2015) (1)
Effects of glycoprotein IIb/IIIa blockers. (2007) (1)
DO STATINS INCREASE BLEEDING RISK IN ANTICOAGULATED INDIVIDUALS (2015) (1)
Emergent angioplasty for acute myocardial infarction at a community hospital without on-site cardiac surgery (2002) (1)
PS1-26: Use of an Electronic Health Record to Facilitate the Enrollment of Patients in Prospective Randomized Clinical Trials: Lessons Learned from STABILITY Trial (2010) (1)
Abstract 179: Ischemic Stroke in Atrial Fibrillation: 30-day Outcomes and Factors Associated with Severity (2015) (1)
Treatment of Coronary Artery Disease and Acute Myocardial Infarction in Hospitals With and Without On-Site Coronary Artery Bypass Graft Surgery (2019) (1)
Detailed intravascular ultrasound analysis after routine high pressure assisted intracoronary stent implantation (1996) (1)
Cyclosporine for Reperfusion Injury After Cardiac Arrest: Too Little Too Late? (2016) (1)
1044-62 Post-market surveillance of the CYPHER sirolimus-eluting stent: One-month clinical results from the United States (2004) (0)
LOW RATES OF ORAL ANTICOAGULATION USE AND POOR OUTCOMES AMONG FRAIL PATIENTS HOSPITALIZED WITH ATRIAL FIBRILLATION (2019) (0)
Abstract 17432: Specific Care Process Implementation Associated With Improved Reperfusion Times Across Multiple STEMI Networks: Insights From The AHA Mission: Lifeline STEMI Accelerator Program (2015) (0)
ASSOCIATIONS BETWEEN DUAL ANTIPLATELET THERAPY CESSATION AND MACE DUE TO STOPPING ONE OR BOTH DRUGS: INSIGHTS FROM THE PARIS REGISTRY (2014) (0)
Abstract 3342: Adequacy of Inclusion of Post-Procedural Bleeding in a Composite End Point for Assessment of Outcome After Percutaneous Coronary Intervention. (2007) (0)
IMPACT OF REGIONAL SYSTEMS OF CARE ON DISPARITIES OF CARE IN FEMALES AND BLACKS PRESENTING WITH ST ELEVATION MYOCARDIAL INFARCTION (2016) (0)
TCT-389 Acute and 6-Month Clinical and Echocardiographic Outcomes of the First-In-Human Experiences with the Implantation of a Novel Catheter-based Ventricular Partitioning Device in Patients with Ischemic Heart Failure and Dilated Left Ventricle (2012) (0)
Lipoprotein-associated phospholipase A2 is associated with angiographic coronary artery disease on univariate analysis but loses independent predictive value in a multivariate model (2003) (0)
Abstract 18402: Impact of the Use of Different Bleeding Scales on the Rate of 6-Month Bleeding After PCI: Results from the PARIS Registry (2012) (0)
Abstract 16705: Lower Education Level is Associated with Non-Adherence to Dual Antiplatelet Therapy After PCI: 6-Month Results from PARIS (2012) (0)
FREQUENCY AND IMPACT OF SINGLE VERSUS DUAL ANTIPLATELET CESSATION ON ADVERSE CARDIAC EVENTS: RESULTS FROM THE PARIS REGISTRY (2013) (0)
878-3 Subgroup analysis of the impact of the glycoprotein IIb/IIIa inhibitor abciximab in patients undergoing elective stent placement >2 hours after treatment with a 600 milligram loading dose of clopidogrel: Results from the ISAR REACT trial (2004) (0)
1097-94 Early versus delayed intervention in non-ST-elevation acute coronary syndromes: A natural experiment from the CRUSADE initiative (2004) (0)
CLOPIDOGREL WITH AND WITHOUT PROTON PUMP INHIBITOR USE: A PARIS REGISTRY ANALYSIS (2014) (0)
TCT-388 Multi-slice Computer Tomography Analysis of Percutaneous Ventricular Restoration (PVR) using the Parachute Device in Patients with Heart Failure Post Anterior Wall Myocardial Infarction: First-In-Man Experience (2012) (0)
Abstract MP07: Rising Incidence and Prevalence of Atrial Fibrillation from 2004 to 2013: A Community-Based Study Using Electronic Medical Records (2015) (0)
Restenosis is not increased in mild or moderate chronic kidney disease: Results from the PRESTO trial (2003) (0)
Abstract 057: Understanding of Treatment Strategies Among Patients Newly Diagnosed With Atrial Fibrillation: Findings From SATELITTE (2017) (0)
RELATIONSHIP BETWEEN BLEEDING AND MORTALITY IN PATIENTS ON DUAL ANTIPLATELET THERAPY VS ASPIRIN ALONE: RESULTS FROM THE CHARISMA TRIAL (2011) (0)
Relation of Operator Volume and Access Site to Short-Term Mortality in Radial Versus Femoral Access for Primary Percutaneous Coronary Intervention. (2022) (0)
The Cook Inc. Gianturco-Roubin Flex-Stent (1996) (0)
Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis. (2000) (0)
Abstract 13139: Antithrombotic Use at Time of Incident Stroke among Individuals With Recent Atrial Fibrillation (2013) (0)
IMPROVED CASE MIX INDEX DUE TO EMBEDDING CLINICAL DOCUMENTATION IMPROVEMENT SPECIALISTS ON AN INPATIENT CARDIOLOGY SERVICE AT A TERTIARY MEDICAL CENTER (2015) (0)
Managing 30-day readmissions after Pci Understanding the causes and identifying risk factors to prevent readmission (0)
GUSTO V: should it affect clinical practice? Global Use of Strategies to Open Occluded Coronary Arteries. (2002) (0)
Renal insufficiency and its relation to ischemic and bleeding outcomes with tirofiban versus abciximab in the TARGET trial (2002) (0)
Evaluation of paclitaxel eluting stents in single and multivessel coronary artery disease using established and novel stent platforms: An interim analysis of the randomized, blinded COSTAR II trial (2006) (0)
Review: early statin therapy does not reduce the composite endpoint of death, MI, or stroke in acute coronary syndromes. (2006) (0)
STEMI Care in Poland and the United States: Both Have Some Distance Yet to Travel. (2017) (0)
Abstract WP264: Early Rehospitalization for Stroke Higher With Aspirin or No Antithrombotic Therapy Than With Oral Anticoagulation in an Unselected Population of Patients With Atrial Fibrillation (2018) (0)
Fractional flow reserveguided PCI reduced major adverse cardiac outcomes compared with angiography-guided PCI in multivessel CAD (2009) (0)
Frequency of allergy to ticlopidine among patients allergic to clopidogrel (and vice versa) (2008) (0)
IMPACT OF PRE-HOSPITAL ECG ON TIME TO TREATMENT AND CLINICAL OUTCOME IN A RURAL REGIONAL STEMI NETWORK (2013) (0)
ACP Journal Club. Fractional flow reserve-guided PCI reduced major adverse cardiac outcomes compared with angiography-guided PCI in multivessel CAD. (2009) (0)
Is the risk of restenosis after a second PTCA higher among patients with a history of prior restenosis at another site (1991) (0)
A radial resolution to a warfarin worry (2015) (0)
Transport and centralization of acute coronary syndrome care (2004) (0)
Abstract 100: Influence of Race on Presentation, Treatment, and Outcome Among Patients With Atrial Fibrillation-related Ischemic Stroke (2015) (0)
Evidence of equivalent clinical outcome after ideal angioplasty results with or without stent use (1998) (0)
Outcome of early revascularization in elderly patients with cardiogenic shock in acute myocardial infarction (2002) (0)
Abstract 1993: Can STEMI Patients Transferred For 1{degrees} Angioplasty Receive Treatment Within 90-Minutes in a Rural Setting? (2007) (0)
P3840Use of oral anticoagulation is less among hospitalized patients with paroxysmal compared to persistent or permanent atrial fibrillation (2018) (0)
The relative safety and efficacy of clopidogrel in women and men: Meta-analysis of 79,613 patients enrolled in CREDO, CURE, CLARITY-TIMI 28, COMMIT, and CHARISMA (2007) (0)
Review: rescue percutaneous coronary intervention but not repeated fibrinolysis is effective for failed fibrinolysis in STEMI. (2007) (0)
Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: insights from the SOS (Stenting of Saphenous Vein Grafts) trial. (2011) (0)
1063-54 Long-term clopidogrel therapy is particularly beneficial for patients requiring repeat revascularization after an initial percutaneous coronary intervention (2004) (0)
Frequency of Allergic or Hematologic Adverse Reactions to Ticlopidine Among Patients With Allergic or Hematologic Adverse Reactions to Clopidogrel (2009) (0)
ASSOCIATIONS BETWEEN DIFFERENT MODES OF DAPT CESSATION AND MAJOR ADVERSE EVENTS AT 6 MONTHS AND BEYOND: INSIGHTS FROM THE PARIS REGISTRY (2014) (0)
FREQUENCY AND LONG-TERM OUTCOME OF PATIENTS WITH ASYMPTOMATIC LEFT-VENTRICULAR DYSFUNCTION (2015) (0)
Adding pre-procedural clopidogrel to aspirin may reduce cardiovascular events in people scheduled for percutaneous coronary intervention (2003) (0)
The value of registries and the importance of evidence-based medicine (2006) (0)
Review: reduction in resting heart rate after taking β-blockers or calcium-channel blockers reduce mortality and morbidity after MI (2008) (0)
Bivalirudin Provides Increasing Benefit With Declining Renal Function in Percutaneous Coronary Intervention: A Meta-Analysis of 5,035 Patients Enrolled in Three Randomized Trials (2003) (0)
PREDICTORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 MASS AND ACTIVITY LEVELS AMONG PATIENTS WITH STABLE AND ACUTE CORONARY SYNDROMES: A CREDO BIOMARKER SUBSTUDY (2010) (0)
Immediate and Late Outcomes After Direct Stent Implantation Without Balloon (2016) (0)
Short-term Deaths After Percutaneous Coronary Intervention Discharge: Prevalence, Risk Factors, and Hospital Risk-Adjusted Mortality (2023) (0)
Medium-dose hirudin was superior to heparin in preventing ischemic events in patients with acute myocardial ischemia. (1998) (0)
Abstract 18759: Safety and Cost Effectiveness of Same Day Discharge After Elective Percutaneous Coronary Interventions: A Large Rural Single Center Experience (2015) (0)
U Clinical Progress Series Inferior Myocardial Infarction High-Risk Subgroups (2005) (0)
TCT-239 Efficacy and Safety of Short-Infusion Tirofiban in Patients Undergoing Percutaneous Coronary Intervention: The SAVI-PCI Trial (2021) (0)
Should routine platelet testing be done on all patients undergoing percutaneous coronary intervention? Routine Platelet Testing Should Not Be Performed on All Patients Undergoing Percutaneous Coronary Intervention (2010) (0)
1028-170 Higher levels of lipoprotein-associated phospholipase A2 are associated with higher incidence of cardiovascular events at follow-up independent of C-reactive protein (2004) (0)
408-5 Plasma leptin level is an important and independent predictor of prognosis in patients with established coronary atherosclerosis (2004) (0)
Fate of nonflow-limiting dissections after treatment with iridium-192 therapy: results from the GAMMA I and II trials (2002) (0)
Abstract 20198: Length of Stay and 30 Day Mortality in Patients Suffering an Uncomplicated ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention in New York State (2014) (0)
PS2-18: Characterization of the Health Care of Patients with Impaired Fasting Glucose Compared to Those with Normal Fasting Glucose Managed in a Rural Multi-Specialty Medical Group Practice (2011) (0)
CLINICAL AND ECONOMIC IMPACT OF AN INTEGRATED HEALTHCARE SYSTEM ON PATIENTS WITH NEW ONSET ATRIAL FIBRILLATION AND FLUTTER (2013) (0)
Assessment of advantages and disadvantages of agents used for therapeutic anticoagulation. (2012) (0)
Percutaneous transluminal coronary angioplasty improved long-term angina status more than medical therapy in coronary artery disease. (2004) (0)
IMPROVED OUTCOMES WITH DRUG ELUTING VERSUS BARE METAL STENTS IN SAPHENOUS VEIN GRAFT INTERVENTION: A REPORT FROM THE EVALUATION OF DRUG-ELUTING STENTS AND ISCHEMIC EVENTS (EVENT) REGISTRY (2011) (0)
Can Standardization of Perinatal Care Process Reduce Cost of Care ? Evidence from an Integrated Healthcare Delivery System in the United States (2015) (0)
dietary perturbation -synthase and apolipoprotein E double knockout mice with and without β Hyperhomocysteinemia accelerates atherosclerosis in cystathionine (2013) (0)
Infarction Reperfusion for ST-Segment Elevation Myocardial Implementation of a Statewide System for Coronary (2007) (0)
Management of Unstable Angina and Non-ST Elevation Myocardial Infarction (2003) (0)
Thrombocytopenia Is More Common and Nadir Occurs Earlier with Unfractionated Heparin Than with Low Molecular Weight Heparin - Results from the Prospective Catch Registry. (2004) (0)
The Role of P2Y12 Blockade in Acute Coronary Syndromes and in the Catheterization Laboratory (2004) (0)
P 2 Y 12 Assay : Impact on Thrombosis and Safety ( GRAVITAS ) Trial Intervention : A Time-Dependent Analysis of the Gauging Responsiveness With a Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary (2011) (0)
Contemporary use of platelet function and pharmacogenomic testing among acute myocardial infarction patients treated with PCI in the United States: insights from the TRANSLATE-ACS study (2013) (0)
TEMPORAL ASSOCIATIONS BETWEEN TIME AFTER PERCUTANEOUS CORONARY INTERVENTION, DUAL ANTIPLATELET THERAPY CESSATION AND STENT THROMBOSIS IN THE CONTEMPORARY PCI ERA: INSIGHTS FROM THE PARIS REGISTRY (2014) (0)
Bivalirudin reduced major bleeding and adverse events in patients with STEMI having PCI (2008) (0)
Platelet glycoprotein IIb/IIIa receptor antagonists: a guide to patient selection and optimal use (2008) (0)
Reply: Is CABG Superior to DES for Repeat Revascularization in Patients With Isolated Proximal LAD Disease? (2015) (0)
Overlapping paclitaxel elating stents: Early outcomes in the COSTAR II study (2006) (0)
Pharmacology of Intravenous Glycoprotein IIb/IIIa Antagonists (2009) (0)
radial access in 81% of patients. Radial access decreases bleeding complications, (2014) (0)
Abstract 14860: Frequency of Allergic or Hematologic Adverse Reactions to Prasugrel in Patients with a Previous Allergic or Hematologic Adverse Reaction to Clopidogrel (2012) (0)
CLINICAL RESEARCH Interventional Cardiology Influence of Treatment Duration With a 600-mg Dose of Clopidogrel Before Percutaneous Coronary Revascularization (2004) (0)
Increased rates of stent thrombosis among patients with acute coronary syndromes: insights from two large oral IIb/IIIa antagonist trials (2001) (0)
IMPACT OF AGE ON THE MODES OF DUAL ANTIPLATELET THERAPY CESSATION: ANALYSIS FROM THE PARIS (PATTERNS OF NON-ADHERENCE TO ANTI-PLATELET REGIMENS IN STENTED PATIENTS) REGISTRY (2015) (0)
Abstract 20412: Growing Burden of Recognized Atrial Fibrillation in a Large Health Care System: Temporal Trends in the Incidence, Prevalence, and Survival of Atrial Fibrillation From 2004-2016 (2017) (0)
W-K-086 USING HEALTH INFORMATION TECHNOLOGY AND THE STOP QUESTIONNAIRE AS A SELF-DIRECTED AND COST EFFECTIVE STRATEGY TO SCREEN FOR OBSTRUCTIVE SLEEP APNEA (2011) (0)
Perindopril reduced cardiac events in stable coronary artery disease. (2004) (0)
624FO-6 Emergent Angioplaaty for Acute Myocardial Infarction at a Community Hospital Without On-Site Cardiac Surgery (2016) (0)
Aggressive antiplatelet therapy reduced the risk of bleeding complications following stent implantation (1999) (0)
Is 30-Day Mortality after Admission for Heart Failure an Appropriate Metric for Quality? (2017) (0)
Stenting plus abciximab offered the greatest clinical benefits in patients undergoing percutaneous revascularization (1999) (0)
Adjunctive treatment with eplerenone reduced 30-day all-cause mortality in acute myocardial infarction. (2006) (0)
Impact of COVID-19 on percutaneous coronary intervention utilization and mortality in New York. (2023) (0)
Abstract 19058: STEMI Patients Presenting to Non PCI Capable Hospitals in New York State: Treatment Strategies and 30-Day Mortality (2016) (0)
Stents in the elderly for failed PTCA, early and intermediate term results (1996) (0)
Drug-Eluting Coronary Stents (2007) (0)
Has Prasugrel Been Compared Correctly With Clopidogrel in Non–ST-Segment Elevation Acute Coronary Syndrome? (0)
Iconographies supplémentaires de l'article : Comparison of percutaneous interventions for unstable angina pectoris in patients with and without previous coronary artery bypass grafting (2011) (0)
ptimal Timing for the Initiation of reTreatment With 300 mg Clopidogrel efore Percutaneous Coronary Intervention (2016) (0)
Adjunctive treatment with eplerenone reduced 30 day all cause mortality in acute myocardial infarction (2006) (0)
IMPACT OF BODY MASS INDEX ON MAJOR BLEEDING AFTER PCI: ONE-YEAR RESULTS FROM THE MULTICENTER PROSPECTIVE PARIS REGISTRY (2013) (0)
Impact of Clopidogrel Pretreatment on Ischemic Complications of PCI among Bivalirudin-Treated Patients: Results from the EVENT Registry (2010) (0)
TreatmentEnoxaparin may reduce the risk of myocardial infarction among people at increased risk of stent thrombosis, but is unnecessary for most people (2002) (0)
Acute Coronary Syndrome Institutional Protocols (2020) (0)

This paper list is powered by the following services:

Other Resources About Peter B. Berger

en.wikipedia.org

What Schools Are Affiliated With Peter B. Berger?

Peter B. Berger is affiliated with the following schools:

Peter B. Berger's Academic­Influence.com Rankings